Helen Stephens Group LLC Makes New $50,000 Investment in Arbutus Biopharma Co. (NASDAQ:ABUS)

Helen Stephens Group LLC acquired a new stake in Arbutus Biopharma Co. (NASDAQ:ABUS) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 13,000 shares of the biopharmaceutical company’s stock, valued at approximately $50,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. nVerses Capital LLC purchased a new stake in Arbutus Biopharma during the second quarter worth about $34,000. Walleye Trading LLC purchased a new stake in Arbutus Biopharma during the first quarter worth about $36,000. XTX Topco Ltd purchased a new stake in Arbutus Biopharma during the second quarter worth about $53,000. China Universal Asset Management Co. Ltd. increased its stake in Arbutus Biopharma by 66.1% during the first quarter. China Universal Asset Management Co. Ltd. now owns 32,233 shares of the biopharmaceutical company’s stock worth $83,000 after purchasing an additional 12,833 shares during the period. Finally, Price T Rowe Associates Inc. MD increased its stake in Arbutus Biopharma by 22.4% during the first quarter. Price T Rowe Associates Inc. MD now owns 36,388 shares of the biopharmaceutical company’s stock worth $94,000 after purchasing an additional 6,649 shares during the period. 43.79% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on ABUS. Jefferies Financial Group upped their target price on shares of Arbutus Biopharma from $5.00 to $7.00 and gave the stock a “buy” rating in a research note on Thursday, September 5th. JMP Securities upped their target price on shares of Arbutus Biopharma from $4.00 to $5.00 and gave the stock a “market outperform” rating in a research note on Friday, August 2nd. Finally, StockNews.com upgraded shares of Arbutus Biopharma from a “sell” rating to a “hold” rating in a research note on Saturday, August 10th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, Arbutus Biopharma currently has a consensus rating of “Moderate Buy” and an average price target of $5.25.

Arbutus Biopharma Stock Up 1.1 %

Shares of ABUS opened at $3.77 on Wednesday. The stock has a 50 day moving average price of $3.94 and a 200 day moving average price of $3.40. Arbutus Biopharma Co. has a 52-week low of $1.69 and a 52-week high of $4.72.

Arbutus Biopharma (NASDAQ:ABUS) last announced its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.01). The business had revenue of $1.73 million during the quarter, compared to analyst estimates of $1.54 million. Arbutus Biopharma had a negative net margin of 766.20% and a negative return on equity of 66.68%. During the same period last year, the company earned ($0.10) earnings per share. Research analysts anticipate that Arbutus Biopharma Co. will post -0.38 EPS for the current year.

About Arbutus Biopharma

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.